Search results
Showing 331 to 345 of 537 results for syndrome
Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel (HTG320)
Evidence-based recommendations on faecal calprotectin tests for distinguishing between inflammatory bowel diseases (such as Crohn’s disease and ulcerative colitis) and non-inflammatory bowel diseases (such as irritable bowel syndrome).
Biographies for all current members of the diagnostics advisory committee.
This guideline sets out an antimicrobial prescribing strategy for adults with leg ulcer infection. It aims to optimise antibiotic use and reduce antibiotic resistance.
Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia (TA343)
Evidence-based recommendations on obinutuzumab (Gazyvaro) with chlorambucil for untreated chronic lymphocytic leukaemia in adults.
Evidence-based recommendations on bevacizumab (Avastin), with paclitaxel and carboplatin, for treating advanced ovarian cancer in adults.
TYM smartphone otoscope for imaging and videoing the external ear canal and eardrum (MIB134)
NICE has developed a medtech innovation briefing (MIB) on the TYM smartphone otoscope for imaging and videoing the external ear canal and eardrum .
Biographies and registered interests for members of the Technology Appraisal Committee A
Biographies and registered interests for members of the Technology Appraisal Committee A
This guideline covers the care of pregnant women and pregnant trans and non-binary people and their babies during labour and immediately after birth. It focuses on women and pregnant people who give birth between 37 and 42 weeks of pregnancy (‘term’). The guideline helps women and pregnant people to make informed choices about where to have their baby and about their care in labour. It also aims to reduce variation in aspects of care.
View recommendations for NG235Show all sections
Sections for NG235
- Overview
- Recommendations
- Recommendations for research
- Rationale and impact
- Context
- Appendix A: Adverse outcomes for different places of birth
- Appendix B: Outcomes for different places of birth – by BMI at booking
- Appendix C: Outcomes for intravenous remifentanil patient-controlled analgesia (PCA) compared with intramuscular pethidine
This guideline covers recognising and responding to abuse and neglect in children and young people aged under 18. It covers physical, sexual and emotional abuse, and neglect. The guideline aims to help anyone whose work brings them into contact with children and young people to spot signs of abuse and neglect and to know how to respond. It also supports practitioners who carry out assessments and provide early help and interventions to children, young people, parents and carers.
Idiopathic overactive bladder syndrome: botulinum toxin A (ESNM2)
This evidence summary has been replaced by NICE guideline CG171.
the effect of relaxation and biofeedback therapies on [Irritable bowel syndrome] (IBS) symptoms and patient-related outcomes? Any...
Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA394)
Evidence-based recommendations on evolocumab (Repatha) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults.
This quality standard covers diagnosing and managing renal cell carcinoma in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.
View quality statements for QS215Show all sections
Sections for QS215
- Quality statements
- Quality statement 1: Suspected cancer pathway referral
- Quality statement 2: Renal biopsy for small renal lesions
- Quality statement 3: Clinical nurse specialist
- Quality statement 4: Surgery with curative intent
- Quality statement 5: Follow-up imaging
- Quality statement 6: Uro–oncology multidisciplinary team
- About this quality standard
Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia (TA193)
Evidence-based recommendations on rituximab for treating relapsed or refractory chronic lymphocytic leukaemia in adults.